Jaguar Health (JAGX) EBITDA (2014 - 2026)

Jaguar Health (JAGX) has 13 years of EBITDA data on file, last reported at $10.2 million in Q1 2026.

• On a quarterly basis, EBITDA rose 208.08% year-over-year to $10.2 million in Q1 2026; TTM through Mar 2026 was -$26.3 million, a 17.89% increase from a year earlier, with the FY2025 full-year figure at -$45.9 million, down 48.9% from the prior year.
• EBITDA for Q1 2026 stood at $10.2 million, up from -$21.2 million in the prior quarter.
• Over the last five years, EBITDA for JAGX reached as high as $10.2 million in Q1 2026 and fell as low as -$21.2 million in Q4 2025.
• Historically, EBITDA has averaged -$8.0 million across 5 years, with a median of -$8.1 million in 2023.
• Across the five-year window, EBITDA slumped 160.41% in 2025 and jumped 208.08% in 2026, its largest moves.
• Year by year, EBITDA stood at -$6.3 million in 2022, then fell by 20.22% to -$7.6 million in 2023, then slipped by 7.94% to -$8.2 million in 2024, then plunged by 160.41% to -$21.2 million in 2025, then surged by 147.93% to $10.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $10.2 million in Q1 2026, -$21.2 million in Q4 2025, and -$7.2 million in Q3 2025.